All news

PDSB: PDS Biotechnology Corporation filed SEC Form 8-K: Results of...

Alpha Vantage · Quantisnow · · AI-summarised by FinFlash

PDS Biotechnology Corporation announced its Q3 2026 results, reporting a net loss of $7.6 million, an improvement from the previous year. The company also disclosed an initial closing of a PIPE financing up to $22.3 million led by Nant Capital, but flagged going-concern and Nasdaq listing compliance risks due to its cash position of

Read original source

PDSB company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.